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Vascular smooth muscle contains large amounts of the Ca*‘-dependent protease calpain II. In this study, we compared bovine aortic muscle (muscle 
phenotype) to cultured bovine sortie cells of smooth muscle origin (modulated phenotype) with respect to major constituents of the calpnin- 
calpastatin system. Bovine aortic muscle contained only calpain II by activity measurements, Western blot of tissue extracts and Northern blot 
of poly(A)’ RNA. On the other hand, using the same methodologies, both calpains I and II as well as the 1 IO kDa inhibitor protein, calpastatin, 
were identified in cultured bovine aortic cells of smooth muscle origin. We conclude that the phenotypic state of smooth muscle cells is associatsd 
with differential expression of majoe components of the calpain-calpastatin system. Moreover, bovine aortic muscle is the only tissue identified 
to date that contains ca!pain II exclusively. 
Calpain; Calpastatin; Vascular smooth muscle 
I * INTRODl_JCTION 
The calpains are Ca2’-dependent thiol proteases that 
are widely distributed in mammalian tissues [l]. Two 
major enzymes have been identified: calpain I and cal- 
pain II. Both are heterodimers which contain a common 
30 kBa regulatory subunit and unique catalytic subu- 
nits of approximately 80 kDa that are products of dis- 
tinct genes [2]. Calpain I is highly sensitive to Ca2+ and 
is the only calpain found in human platelets and eryth- 
rocytes [l]. Calpain II is found in many tissues, espe- 
cially liver and muscle, and is relatively insensitive to 
Ca’+, requiring concentrations in the millimolar range 
for full activity [2]. 
Calpastatin is a highly specific inhibitor of both cal- 
pains I and II [3]. It, too, is widely distributed in mam- 
malian tissues and cL9NA’s encoding the human liver, 
rabbit skeletal anJ porcine tialdiac calpastatins have 
been sequenced [4,5]. Calpastatin possesses four inhibi- 
tory domains (except the erythrocyte calpastatin which 
has only three) which accounts for the maximal inhibi- 
tory stoichiometry of 1 calpastatin molecule per 4 cal- 
pain molecules [4,5]. 
Although the calpain-calpastatin systems has been 
implicated in a number of cellular processes, increasing 
evidence suggests a modulatory role in cellular prolife- 
ration [6,7]. For example, cell permeant inhibitors of the 
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calpains inhibit mitosis [8]. Calpain II has been sh.own 
to bind to metaphase chromosomes [7]. Quite recently, 
calpain II has been shown to degrade the meiotic cell 
cycle progression factor and metaphase inhibitor, c- 
mos, an event which permits progress into anaphase [SJ. 
Vascular smooth muscle contains relatively large 
amounts of calpain II [lo]. Moreover, this muscle can 
undergo a marked proliferative response as a reaction 
to arterial injury [1 I]. As part of a continuing effort to 
define the function of the calpain-ealpastatin system in 
vascular smooth muscle, we report that calpain II is the 
exclusive isoform present in the contractile phenotype 
of bovine aortic smooth muscle, which is also devoid of 
calpastatin. In addition, our results also show that cul- 
tured bovine aortic cells of smooth muscle origin (mod- 




Most chemical reagents were purchased from the Sigma Chemical 
Company. Supplies for electrophoresis and Western blotting were 
purchased from Rio-Rad, Schleicher and Schu:ll and New England 
Nuclear. Reagents and other materials for r,rolecular biology were 
obtained from IBRE, United States Biochemical, Pharmacia, Promega 
and Stratagene. 
2.2. Methods 
2.2.!. Protein purification and assays. Calpain II was purified from 
bovine aortic smooth muscle as described previously [12]. Calpain I 
was purified from bovine erythrocyta as described by Ando et al. [I 33. 
Calpa.in activhy was measured as trichloroacetic acid-soluble peptides 
liberated from [a-3H]casein under linear reaction conditions [12]. Cal- 
pastatin activity was measured as % inhibition of TCA-soluble pep- 
tides released from [oz-3H]casein by 1.5 ,ug of calpein II under standard 
assay conditions. Fresh bovine aortic muscle or cultured cells were 
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extracted in 5 volumes of 20 mM MOPS, pH 7.0, 10 mh4 EGTA, 5 
mM EDTA, 1 mM dithiothreitol and 0.5% Triton X-100, sonicated 
and sedimented (15 000 x g for 20 min). The supernatants were 
applied to 50 (muscle) or 20 (cells) ml columns of DEAE-Sephacel 
equilibrated in 20 mM MOPS, pH 7.0, 1 mM EC’I’A, I mM EDTA 
and 1 mM dithiothreitol. Fractions of 5 ml or 2 ml, respectively, were 
collected by elution with a NaCl gradient (O-O.5 M) in column equi- 
libration buffer. In addition to activity measurements, the calpains 
and calpastatin were identified by Western blots of 30 ~1 fractions 
applied to 7.5% Porzio gels [14]. Antisera to calpains I and II were 
produced in rabbits [15]. Antiserum to calpastatin was a gift from Dr 
Darrel Goll (University of Arizona). 
2.22. Molcwlor and cellular biology methods. Bovine aortic smooth 
muscle cells were generated by the explantation method [16] and 
grown to confluence in Dulbecco’s Modified Eagles Medium. The 
smooth muscle origin of these cells was confirmed by immuno- 
fluorescence using the anti-u actin antibody, I-IHF-21 6171. A cDNA 
encoding 1.5 kb of calpain I was cloned and sequenced from a rabbit 
brain &@I1 library [lg]. cDNA’s for the calpain II catalytic subunit 
and calpastatin were prepared by the polymerase chain reaction 
(PCW). For calpain II, poly(A)’ RNA was isolated from fresh bovine 
aorta, and cDNA synthesis and amplification were performed as de- 
scribed by others [lst]. PCR probes were synthesized as: (+) strand to 
nucleotides 1-24 and (-) strand to nucleotides 991-1017 in reference. 
Calpastatin cDNA was prepared from rabbit liver poly (A)’ RNA. 
PCR prohles for the liver were: (+) strand to nucleotides 100-123 and 
(-) strand to nucleotides 1123-l 149 in reference i2:]. Poly(A)’ RNA 
was isolated from bovine aorta or cultured celis (1 x 10’ cells) for 








Fig. 2. Western blots of fractions from the DEAE-Sephacel columns. 
Approximately 30 ~1 of every third fraction was subjected to sodium 
dodecylsulfate-polyasrylamide gel electrophoresis and electroblotted 
onto nitrocellulose. The sheets were then incubated with antisera to 
the catalytic subunits of calpain I (1:5000), calpain II (1:5000) or 
calpastatin (1:2500) according to a protocol previously published [26]. 
The lanes of the autoradiogram shown in Fig. 2 correspond to actual 
or theoretical peaks. For bovine aorta, these are: calpain 1, fraction 
46; calpain II, fraction 84;calpastatin, fraction 29. For cultured bovine 
aortic cells, these are: calpain I, fraction 38; calpain II, fraction 69; 
calpastatin, fraction 24. 
reported purification schemes, overlap of calpastatin 
and calpain I activities was evident. 
3. RESULTS 
Elution pi-&es of extracts of bovine aortic smooth 
muscle or cultured bovine aortic cells are shown in Fig. 
1. By activity measurements, only a single peak of cal- 
pain activity was identified in bovine aortic muscle elut- 
ed from the DEAE-Sephacel column at an NaCl con- 
centration of about 0.3 M. No calpastatin or calpain I 
activity was measured. In addition to calpain II activity, 
the extract of cultured bovine aortic cells yielded calpas- 
tatin activity and a small peak of calpain I. As in other 
Verification of results was obtained by Western blot- 
ting of fractions from the DEAE-Sephacel column using 
antisera specific for calpain catalytic subunits and for 
calpastatin. Those fractions corresponding to the peak 
identified by antibody reactivity are shown in Fig. 2. 
For both bovine aortic muscle and cultured cells, the 
peak fraction of calpain II identified by Western blot 
corresponded exactly to the peak fraction identified by 
activity measurements. Calpain I could not be identified 
by Western blot in any fraction of vascular muscle. On 
the other hand, calpain I was detected in the column 
eluate of cultured bovine aortic cells. The peak identi- 





Fig. 3.Northern blots of poly(A)’ RNA from bovine aortic muscle or 
cultured bovine aortic cells. Approximately 2 c(g of poly(A)’ RNA 
prepared from aortic muscle or cells as described under the section, 
Experimental, was subjected to agarose gel electrophoresis in formal- 
dehyde buffer and blotted onto nitrocellulose [22]. cDNA species, 
corresponding to the catalytic subunits of calpains 1 and II and calpas- 
tatin and radiolabeled by nick translation, were hybridized to the 
Fig. 1. DEAE-Sephacel chromatography of extracts of bovine aortic 
muscle (A) or cultured bovine aortic cells (B). Extracts were prepared 
and assayed for activity as described in section 2. Approximately 100 
fractions of either 5 (A) or 2 (B) ml were collected for each run, mRNA as described by others [22]. 
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to overlap with calpastatin (and vice versa) since separa- 
tion of these proteins by chromatography on DEAE- 
Sephacel is incomplete. Confirming the activity meas- 
urements, there was no immunological evidence for cal- 
pastatin in bovine vascular muscle. 
Northern blot analysis of poly(A)+ RNA prepared 
from either bovine aortic muscle or cultured cells is 
shown in Fig. 3. Although no attempt was made to 
quantitate the signal for each of the calpain-calpastatin 
species present, under identical conditions, only calpain 
II mRNA was present in muscle while mRNA species 
for calpains II II and calpastatin were present in the 
cultured cells. These results were confirmatory of both 
activity measurements and Western blots. 
4. DISCIJSSION 
Our study demonstrates that contractile (muscle) and 
cultured (modulated) ph.enotypes of bovine aortic 
smooth muscle express different components of the 
calpain- calpastatin system. Recent studies from our 
laboratory have shown that cell permeant tripeptide 
aldehyde inhibitors of calpains I and II are potent anti- 
mitogens [23]. These results are, in general, comple- 
mentary to the findings of Schollmeyer who showed 
that calpain II facilitated metaphase to anaphase transi- 
tion by binding to chromosomes [i’]. However, many 
complex issues remain including the physiological 
modulation of Cat+ sensitivity of calpain II, the mode 
of activation of either calpain I or II and an explanation 
of how calpastatin inhibition of the calpains is cir- 
cumvented. Moreover, with the exception of c-mos in- 
activation by calpain II in meiotic cells [9], specific sub- 
strates that are targets for activated calpain during cell 
growth and proliferation remain to be identified. 
The situation in vascular muscle is further complicat- 
ed by segregation of the expression of the calpain-cal- 
pastatin system. Vascular calpain II can degrade 
myosin in vitro but the Ca,“+ concentrations required for 
activation of the enzyme are quite high (e.g. > 150 @l) 
[24]. Certain cytoskeletal elements such as dense bodies, 
membrane plaques, filamin and intermediate filaments 
have been shown to be sensitive to calpain proteolysis 
in chemically-skinned smooth muscle [25]. Thus, it is 
possible that calpain II could be involved in contractile 
or cytoskeletal protein turnover or in major changes 
that occur in vascular myocytes in re:,ponje to growth 
factor stimulation. 
It is further interesting that calpastatin expression can 
be segregated from that of calpain II as demonstrated 
by this study. This does not conclusively establish that 
calpastatin is unessential for regulation of calpain II. 
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On the other hand, no one has identified a tissue that 
expresses calpain I that is devoid of calpastatin. Thus, 
it is possible that the major function of calpastatin is to 
regulate proteolytic activity of calpain I. 
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